Aug 23, 2023 / 01:00PM GMT
Operator
Hello, and welcome to the Nykode Therapeutics Q2-2023 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the floor over to your host, CEO, Michael Engsig. Please go ahead, sir.
Michael Engsig - Nykode Therapeutics ASA - CEO
Thank you very much, and welcome to -- everybody joining in for this call. We are once again very happy and pleased to be updating you on what's going on in Nykode Therapeutics over the last quarter. Just for formalities, again, as usual, we assume you're all familiar with our forward-looking statements. And on that note, we'll move forward.
I'm pleased to be joined here today by Agnete Fredriksen, our Co-Founder and Chief Business Officer, as well as Harald Gurvin, our Chief Financial Officer. And together, we'll take you through an update on our business activities and R&D program, as well as the financial results.
If we look at the highlights in Q2 for the 2023 was yes, a very busy and successful and rewarding quarter for us. Most
Q2 2023 Nykode Therapeutics ASA Earnings Call Transcript
Aug 23, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers